Checkpoint Therapeutics (CKPT) Competitors $4.04 +0.02 (+0.50%) As of 01:19 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CKPT vs. RCUS, PAHC, VIR, MLYS, SYRE, NRIX, ZYME, AVXL, DAWN, and GYREShould you be buying Checkpoint Therapeutics stock or one of its competitors? The main competitors of Checkpoint Therapeutics include Arcus Biosciences (RCUS), Phibro Animal Health (PAHC), Vir Biotechnology (VIR), Mineralys Therapeutics (MLYS), Spyre Therapeutics (SYRE), Nurix Therapeutics (NRIX), Zymeworks (ZYME), Anavex Life Sciences (AVXL), Day One Biopharmaceuticals (DAWN), and Gyre Therapeutics (GYRE). These companies are all part of the "pharmaceutical products" industry. Checkpoint Therapeutics vs. Arcus Biosciences Phibro Animal Health Vir Biotechnology Mineralys Therapeutics Spyre Therapeutics Nurix Therapeutics Zymeworks Anavex Life Sciences Day One Biopharmaceuticals Gyre Therapeutics Arcus Biosciences (NYSE:RCUS) and Checkpoint Therapeutics (NASDAQ:CKPT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, community ranking, risk, earnings, profitability, media sentiment and valuation. Which has more volatility & risk, RCUS or CKPT? Arcus Biosciences has a beta of 1.54, indicating that its share price is 54% more volatile than the S&P 500. Comparatively, Checkpoint Therapeutics has a beta of 1.21, indicating that its share price is 21% more volatile than the S&P 500. Do analysts prefer RCUS or CKPT? Arcus Biosciences presently has a consensus price target of $30.25, indicating a potential upside of 281.94%. Checkpoint Therapeutics has a consensus price target of $4.33, indicating a potential upside of 7.26%. Given Arcus Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Arcus Biosciences is more favorable than Checkpoint Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcus Biosciences 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00Checkpoint Therapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Does the MarketBeat Community prefer RCUS or CKPT? Arcus Biosciences received 14 more outperform votes than Checkpoint Therapeutics when rated by MarketBeat users. However, 67.16% of users gave Checkpoint Therapeutics an outperform vote while only 65.33% of users gave Arcus Biosciences an outperform vote. CompanyUnderperformOutperformArcus BiosciencesOutperform Votes19665.33% Underperform Votes10434.67% Checkpoint TherapeuticsOutperform Votes18267.16% Underperform Votes8932.84% Which has better valuation and earnings, RCUS or CKPT? Checkpoint Therapeutics has lower revenue, but higher earnings than Arcus Biosciences. Checkpoint Therapeutics is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcus Biosciences$258M3.23-$307M-$3.10-2.55Checkpoint Therapeutics$41K8,253.82-$51.85M-$1.43-2.83 Does the media refer more to RCUS or CKPT? In the previous week, Arcus Biosciences had 8 more articles in the media than Checkpoint Therapeutics. MarketBeat recorded 9 mentions for Arcus Biosciences and 1 mentions for Checkpoint Therapeutics. Checkpoint Therapeutics' average media sentiment score of 1.89 beat Arcus Biosciences' score of 0.70 indicating that Checkpoint Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Arcus Biosciences Positive Checkpoint Therapeutics Very Positive Is RCUS or CKPT more profitable? Checkpoint Therapeutics has a net margin of 0.00% compared to Arcus Biosciences' net margin of -102.66%. Checkpoint Therapeutics' return on equity of 0.00% beat Arcus Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Arcus Biosciences-102.66% -45.59% -22.38% Checkpoint Therapeutics N/A N/A -659.07% Do institutionals and insiders believe in RCUS or CKPT? 92.9% of Arcus Biosciences shares are held by institutional investors. Comparatively, 22.0% of Checkpoint Therapeutics shares are held by institutional investors. 12.3% of Arcus Biosciences shares are held by insiders. Comparatively, 2.1% of Checkpoint Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryArcus Biosciences beats Checkpoint Therapeutics on 11 of the 19 factors compared between the two stocks. Remove Ads Get Checkpoint Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CKPT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CKPT vs. The Competition Export to ExcelMetricCheckpoint TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$338.41M$6.30B$5.32B$7.42BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-2.206.7721.7317.75Price / Sales8,253.82222.97372.3693.57Price / CashN/A65.6738.1534.64Price / Book-8.605.806.393.97Net Income-$51.85M$142.23M$3.20B$247.37M7 Day Performance1.25%3.39%2.11%1.02%1 Month Performance1.76%-13.52%-9.13%-6.65%1 Year Performance139.05%-12.08%9.92%0.06% Checkpoint Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CKPTCheckpoint Therapeutics2.2196 of 5 stars$4.04+0.5%$4.33+7.3%+133.7%$338.41M$41,000.00-2.2010Positive NewsRCUSArcus Biosciences2.448 of 5 stars$7.28+5.9%$30.25+315.8%-50.9%$768.03M$258M-2.32500PAHCPhibro Animal Health3.8293 of 5 stars$18.67-2.7%$21.00+12.5%+27.3%$758.14M$1.11B39.001,860News CoverageVIRVir Biotechnology2.6721 of 5 stars$5.53-1.0%$35.67+545.6%-34.4%$755.80M$63.71M-1.41580Short Interest ↑MLYSMineralys Therapeutics2.3931 of 5 stars$12.01-3.2%$33.00+174.9%+12.5%$751.54MN/A-3.2928Insider TradeShort Interest ↑High Trading VolumeSYRESpyre Therapeutics1.6536 of 5 stars$12.34-3.5%$50.33+307.9%-65.8%$734.83M$890,000.00-1.63100NRIXNurix Therapeutics2.1174 of 5 stars$9.70+0.1%$30.88+218.4%-36.5%$733.77M$54.55M-3.33300ZYMEZymeworks2.6553 of 5 stars$10.43-4.8%$21.00+101.4%+20.4%$725.83M$76.30M-6.95460Positive NewsAVXLAnavex Life Sciences3.3951 of 5 stars$8.35+1.9%$44.00+427.1%+115.6%$715.73MN/A-15.3040Gap UpDAWNDay One Biopharmaceuticals2.4544 of 5 stars$7.03-2.7%$32.29+359.6%-48.1%$709.28M$131.16M-6.7960GYREGyre Therapeutics0.1347 of 5 stars$7.64+10.4%N/A-49.0%$705.46M$105.76M150.7240Short Interest ↑Gap DownHigh Trading Volume Remove Ads Related Companies and Tools Related Companies Arcus Biosciences Competitors Phibro Animal Health Competitors Vir Biotechnology Competitors Mineralys Therapeutics Competitors Spyre Therapeutics Competitors Nurix Therapeutics Competitors Zymeworks Competitors Anavex Life Sciences Competitors Day One Biopharmaceuticals Competitors Gyre Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CKPT) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Checkpoint Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Checkpoint Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
